12. Herceptin

Herceptin won a breast cancer nod alongside Perjeta in June. (Roche)

Company: Roche
2019 sales: $6.08 billion
Projected 2026 sales: $2.08 billion
Projected CAGR: -14%
Used for: HER2-positive breast cancer, stomach cancer

Like Roche's other two top-selling oncology drugs, Avastin and Rituxan, breast cancer med Herceptin faced U.S. biosimilar challengers for the first time in 2019. Unlike Herceptin's portfolio mates, however, Roche may have found a path forward for the blockbuster med as part of a combo therapy. 

Herceptin hit $6.08 billion in sales in 2019, but those peak sales will soon be a thing of the past. Evaluate Pharma forecast that Roche's drug will reach just $2.08 billion in sales in 2026 with copycats on the market. 

But while Herceptin's solo days as one of pharma's top-selling drugs are likely coming to a close, a combination of Herceptin and another Roche drug could keep the therapy relevant for years to come. 

RELATED: Roche wards off Herceptin copycats with new, easy-to-use Perjeta combo product

12. Herceptin

Suggested Articles

The next wave of immuno-oncology R&D includes drugs that interact with a wide range of emerging immune targets, including TIGIT and CD47.

Emerging targets like KRAS, MET and RET are inspiring novel kinase inhibitor development and fueling billions in pharma deals.

Despite the rise of cell therapies to treat cancer, R&D centered on novel tyrosine kinase inhibitors and immuno-oncology targets is booming.